Risk-adaptive therapy guided by dynamic ctDNA in nasopharyngeal carcinoma - PubMed
14 hours ago
- #risk-adaptive therapy
- #ctDNA
- #nasopharyngeal carcinoma
- The EP-STAR trial investigated a risk-adaptive treatment (RAT) strategy guided by circulating tumour DNA (ctDNA) dynamics in nasopharyngeal carcinoma.
- Patients received standard-of-care gemcitabine-cisplatin neoadjuvant chemotherapy (GP-NAC), followed by RAT or standard chemoradiotherapy based on ctDNA clearance.
- The RAT group showed significantly improved 3-year failure-free survival (FFS) of 89.1% compared to the no-RAT cohort.
- The hazard ratio for FFS was 0.41, indicating a substantial benefit from the RAT strategy.
- The study suggests that ctDNA-driven RAT could challenge traditional fixed-course treatment approaches, improving survival outcomes.
- The treatment was well-tolerated with no treatment-related deaths reported.